Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Founded Year



Series B | Alive

Total Raised


Last Raised

$3.25M | 15 yrs ago

About H-Phar

Developer of candidate drugs. The company develops drugs in the sectors of immune-modulator therapeutics inhibiting graft rejection, anti-viral applications of the zinc finger ejector in the field of haemorrhagic fever and oncoviruses, anti-HIV drugs, and low molecular weight azo-compounds.

H-Phar Headquarter Location

Chaussée de Bruxelles 141

Jumet, 6040,


32 10 41 70 8

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing H-Phar

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

H-Phar is included in 1 Expert Collection, including Biopharmaceuticals.



5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.